Mawson Infrastructure (MIGI) 10-K 2 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 01, 2016	Jun. 30, 2015
Document and Entity Information
Entity Registrant Name	OphthaliX, Inc.
Entity Central Index Key	1,218,683
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		10,441,251
Entity Public Float			$ 3,441,848

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Dec. 31, 2015		Dec. 31, 2014
CURRENT ASSETS:
Cash and cash equivalents		$ 42		$ 9
Investment in Parent Company (Note 3)		$ 658		794
Prepaid expenses				209
Total current assets		$ 700		1,012
PROPERTY AND EQUIPMENT, NET			[1]	1
Total assets		$ 700		1,013
CURRENT LIABILITIES:
Parent Company (Note 9)		3,690		2,457
Other accounts payable and accrued expenses		291		246
Total current liabilities		$ 3,981		$ 2,703
NON-CURRENT LIABILITIES:
Derivative related to Service Agreement (Note 4)	[1]
Share capital
Preferred Stock - Authorized: 1,000,000 shares at December 31, 2015 and 2014, Issued and Outstanding: 0 shares at December 31, 2015 and 2014
Common Stock of $0.001 par value - Authorized: 100,000,000 shares at December 31, 2015 and 2014, Issued and Outstanding: 10,441,251 shares at December 31, 2015 and 2014		$ 10		$ 10
Additional paid-in capital		5,516		5,494
Accumulated other comprehensive income (loss)		(34)		102
Accumulated deficit		(8,773)		(7,296)
Total stockholders' deficiency		(3,281)		(1,690)
Total liabilities and stockholders' deficiency		$ 700		$ 1,013
[1]	Represents an amount lower than $1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred Stock, shares authorized	1,000,000	1,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common stock shares issued	10,441,251	10,441,251
Common Stock, shares outstanding	10,441,251	10,441,251

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating expenses:
Research and development	$ 812	$ 721
General and administrative	573	425
Total operating expenses	1,385	1,146
Financial expenses, net (Note 8)	92	49
Net loss	$ 1,477	$ 1,195
Net loss per share:
Basic and Diluted loss per share	$ 0.14	$ 0.11
Weighted average number of shares of Common Stock used in computing basic and diluted net loss per share	10,441,251	10,441,251
Available-for-sale investments:
Changes in net unrealized loss	$ 136	$ 381
Total other comprehensive loss	136	381
Comprehensive loss	$ 1,613	$ 1,576

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) - USD ($) $ in Thousands	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive income
Balance at Dec. 31, 2013	$ (139)	$ 10	$ 5,469	$ (6,101)	$ 483
Balance, Shares at Dec. 31, 2013		10,441,251
Stock based compensation	25		$ 25
Unrealized loss from investment in Parent Company	(381)				$ (381)
Net loss	(1,195)			$ (1,195)
Balance at Dec. 31, 2014	(1,690)	$ 10	$ 5,494	$ (7,296)	$ 102
Balance, Shares at Dec. 31, 2014		10,441,251
Stock based compensation	22		$ 22
Unrealized loss from investment in Parent Company	(136)				$ (136)
Net loss	(1,477)			$ (1,477)
Balance at Dec. 31, 2015	$ (3,281)	$ 10	$ 5,516	$ (8,773)	$ (34)
Balance, Shares at Dec. 31, 2015		10,441,251

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (1,477)	$ (1,195)
Adjustments to reconcile net loss to net cash used in operating activities:
Decrease (increase) in prepaid expenses	209	(189)
Increase (decrease) in other accounts payable and accrued expenses	45	(17)
Increase in Parent company balance	$ 1,233	970
Change in fair value of the derivative related to Service Agreement		(7)
Stock based compensation	$ 22	$ 25
Depreciation	1		[1]
Net cash used in operating activities	33	$ (413)
Cash flows from investing activities:
Purchase of property and equipment	(3)
Proceeds from sale of property and equipment	$ 3
Net cash provided by investing activities
Cash flows from financing activities:
Net cash provided by financing activities
Change in cash and cash equivalents	$ 33	$ (413)
Cash and cash equivalents at the beginning of the year	9	422
Cash and cash equivalents at the end of the year	$ 42	$ 9
[1]	Represents an amount lower than $1

General

General	12 Months Ended
	Dec. 31, 2015
General [Abstract]
GENERAL	NOTE 1:- GENERAL a. OphthaliX Inc. (the "Company" or "OphthaliX"), originally incorporated in the State of Nevada on December 10, 1999 under the name Bridge Capital.com Inc., was a nominally capitalized corporation that did not commence its operations until it changed its name to Denali Concrete Management Inc. ("Denali"), in March 2001. Denali was a concrete placement company specializing in providing concrete improvements in the road construction industry. In December 2005, the Company ceased its principal business operations and focused its efforts on seeking a business opportunity, becoming a public shell company in the U.S. Eye-Fite Ltd. ("Eye-Fite" or the "Subsidiary") was founded on June 27, 2011 in contemplation of the execution of a transaction between Can-Fite BioPharma Ltd. (the "Parent company" or "Can-Fite"), a public company in Israel and U.S, and the Company, as further detailed in Note 1b below (the “Reverse Recapitalization”). Can-Fite granted Eye-Fite an exclusive worldwide license for a therapeutic drug, CF101, solely in the field of ophthalmic diseases (the “License Agreement”). The Company conducts its research and development activities through Eye-Fite Ltd. See also Note 1b2. Upon consummation of the Reverse Recapitalization, Denali changed its name to OphthaliX Inc. and also changed its corporate domicile from the state of Nevada to the state of Delaware. b. Reverse Recapitalization and related arrangements: 1. Recapitalization: On November 21, 2011 (the "Closing Date"), Can-Fite purchased 8,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in exchange for all of the issued and outstanding ordinary shares of Eyefite pursuant to the terms of a stock purchase agreement (the “Purchase Agreement”). As a result, Eyefite became a wholly-owned subsidiary of the Company and Can-Fite became its majority stockholder and a parent. Also on November 21, 2011, the Company issued a warrant to Can-Fite by which Can-Fite has the right, until the earlier of (a) the November 21, 2016 and (b) the closing of the acquisition of the Company by another entity, resulting in the exchange of the Company’s outstanding common shares such that its stockholders prior to such transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity, to convert its right to the Additional Payment (as defined below) into 480,022 shares of Common Stock (subject to adjustment in certain circumstances). The per share exercise price for the shares is $5.148. On November 21, 2011, the Company completed a private placement of shares of its common stock for gross proceeds of $3,330 through the sale of 646,776 shares of Common Stock to third party investors and sold 466,139 shares of Common Stock to Can-Fite in exchange for 714,922 ordinary shares of Can-Fite, valued at $2,400 and 97,112 shares to Can-Fite for gross proceeds of $500,000. In addition, the Company issued to Can-Fite and each of the other investors, for each four shares of the Company’s common stock purchased in the financing, nine warrants valid for a period of five years from the closing of the financing to acquire two shares of the Company for an exercise price of $7.74. On June 17, 2013, the Company sold 268,095 Can-Fite ordinary shares for a total consideration of $511. As of December 31, 2015, the Company holds 446,827 Can-Fite ordinary shares, representing approximately 1.6% of Can-Fite's outstanding share capital. The transaction was accounted for as a reverse recapitalization which is outside the scope ASC 805, Business Combinations. Under reverse capitalization accounting, Eye-Fite is considered the acquirer for accounting and financial reporting purposes, and acquired the assets and assumed the liabilities of the Company. Assets acquired and liabilities assumed are reported at their historical amounts. Consequently, the consolidated financial statements of the Company reflect the operations of the acquirer for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former shareholders of the legal acquirer and a recapitalization of the equity of the accounting acquirer. These consolidated financial statements include the accounts of the Company since the effective date of the reverse capitalization and the accounts of Eye-Fite since inception. 2. License and research and development services from Can-Fite: In connection with the consummation of the Reverse Recapitalization, the Company through EyeFite and Can-Fite entered into a license agreement, pursuant to which Can-Fite granted to EyeFite a sole and exclusive worldwide license for the use of CF101, solely in the field of ophthalmic diseases ("CF101"). In connection with the License Agreement, referred to above, Eye-Fite was obligated to make to the U.S. National Institutes of Health ("NIH"), with regard to the patents of which are included in the license to Eye-Fite, for as long as the license agreement between Can-Fite and NIH remains in effect, a nonrefundable minimum annual royalty fee and potential future royalties of 4.0% to 5.5% on net sales. In addition, the Company was obligated to make certain milestone payments to NIH ranging from $25 to $500 upon the achievement of various development milestones for each indication. In June 2015, the license agreement between Can-Fite and NIH terminated due to patent expiration. As of December 31, 2015, the Company accrued an amount of $100 related to its DES Phase III clinical trial and $75 related to its Phase II glaucoma Phase II clinical trial. Eye-Fite will also be required to make payments of 20% of sublicensing revenues, excluding royalties and net of the required milestone payments. During 2015, the Company did not reach any milestone or generate revenue that would trigger additional payments to Can-Fite. In addition, following the closing of the Reverse Recapitalization, an agreement was signed between Can-Fite, OphthaliX and Eye-Fite (the "Service Agreement"). According to the Service Agreement, Can-Fite will manage the research and development activities relating to pre-clinical and clinical studies for the development of the ophthalmic indications of CF101. According to the Service Agreement, in consideration for Can-Fite's services, Eye-Fite will pay to Can-Fite a service fee (consisting of all expenses and costs incurred by Can-Fite plus 15%). As part of the Service Agreement, the Company is required to pay Can-Fite additional payments from future proceeds (due to commercialization or sublicense agreement) in relation to CF101 (the “Additional Payment”). Can-Fite has the right to exchange such future payments for additional shares of OphthaliX upon payment of an exercise price. For additional information refer to Note 4. c. During the year ended December 31, 2015 and 2014, the Company incurred operating losses amounting to $1,385 and $1,146, respectively. The Company will be required to obtain additional liquidity resources in the near term in order to support the commercialization of its products and maintain its research and development activities. The Company is addressing its liquidity issues by implementing initiatives to raise additional funds as well as other measures that will allow it to cover its anticipated budget deficit. Such initiatives include a plan to monetize part or all of the Company's investment in Can-Fite's ordinary shares. In addition, in February 2013 Can-Fite issued to the Company a formal letter, which has been updated periodically (most recently in August 2015), stating that Can-Fite agrees to defer payments owing to it under the Services Agreement from January 31, 2013 for the performance of the clinical trials of CF101 in ophthalmic indications until the completion of fundraising by the Company sufficient to cover such deferred payments. Also, in August 2015, Can-Fite issued a financial support letter pursuant to which it committed to cover any shortfall in the costs and expenses of operations of the Company which are in excess of the Company's available cash to finance its operations, including cash generated from any future sale of Can-Fite shares held by the Company. Both letters will expire in October 2016 and any related balance shall bear an interest at a rate of 3% per annum. As of December 31, 2015, the deferred payments to Can-Fite totaled $3,690 (also see Note 9). There are no assurances, however, that the Company will be able to obtain an adequate level of financial resources that are required for the short and long-term development and commercialization of its product candidates. According to management estimates, liquidity resources as of December 31, 2015, together with the support letters from the Parent Company described above, will be sufficient to maintain the Company's operations at least through October 2016. The Company's inability to raise funds to conduct its research and development activities will have a severe negative impact on its ability to remain a viable company. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). a. Use of estimates: The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimat b. Financial statements in U.S. dollars: The accompanying financial statements have been prepared in U.S. dollars, the functional and reporting currency of the Company. Although the majority of the Company and its Subsidiary's operations are conducted in Israel, most of their expenses are in U.S dollar. Therefore, the Company's management believes that the U.S dollar is the functional currency of the primary economic environment in which the Company and its Subsidiary operate. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars in accordance with ASC 830-10, "Foreign Currency Matters". All transactions gains and losses of the re-measurement of monetary balance sheets items are reflected in the consolidated statements of comprehensive loss as financial income or expenses, as appropriate. c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its Subsidiary. Intercompany transactions and balances have been eliminated upon consolidation. d. Cash and cash equivalents: Cash equivalents include short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less from time of deposit. e. Prepaid expenses: Prepaid expenses are mainly composed of clinical trials drug-kits which expense based on a percentage of completion method of the related clinical trials. f. Investment in Parent Company: The Company’s investment is its Parent Company’s securities are classified as available-for-sale carried at fair value, with unrealized gains and losses reported as a separate component of stockholders' equity under accumulated other comprehensive income in the consolidated balance sheets. Realized gains and losses on sales of available-for-sale securities are included as financials income, net in the consolidated statements of comprehensive loss. The Company recognizes an impairment charge when a decline in the fair value of its investments in securities is below the cost basis of such securities is judged to be other than temporary. Factors considered in making such a determination include the duration and severity of the impairment, the reason for the decline in value, the potential recovery period and the Company's intent to sell, including whether it is more likely than not that the Company will be required to sell the investment before recovery of cost basis. For securities that are deemed other-than-temporarily impaired, an entity should recognize the difference between the cost basis of the impaired equity security and the fair value on the measurement date, as an other-than-temporarily impairment loss as part of financial income, net in the statement of comprehensive loss. The fair value on measurement date should be considered the equity security’s new cost basis. Unrealized gains and losses previously recorded through OCI, including the tax effects, should also be reversed. The new cost basis should not be changed for subsequent increases in fair value. After an impairment loss is recognized for individual equity securities classified as available for sale, future increases or decreases in fair value (presuming no additional other-than-temporarily impairments exist) are included in OCI. As of December 2015 and 2014 no impairment was recognized. g. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets at the following annual rates: % Computers, and peripheral equipment 33 h. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360, "Property, Plant and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. As of December 31, 2015 and 2014, no impairment losses have been identified. i. Research and development expenses: All research and development costs are charged to the consolidated statements of comprehensive loss, as incurred. j. Accounting for stock-based compensation: The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation" ("ASC 718"). ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company's consolidated statements of comprehensive loss. The Company recognizes compensation expenses for the value of its awards granted based on the accelerated recognition method over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company estimates the fair value of stock options granted using the binomial option pricing-model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the early exercise multiply. Expected volatility was calculated based upon historical volatilities of similar entities in the related sector index. The early exercise multiply is representing the value of the underlying stock as a multiple of the exercise price of the option which, if achieved, results in exercise of the option. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. k. Basic and diluted net loss per share: Basic net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each period. Diluted net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each period, plus dilutive potential Common Stock considered outstanding during the period, in accordance with ASC topic 260, "Earnings Per Share" ("ASC 260"). The total weighted average number of shares related to the outstanding warrants and options excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,320,948 and 1,453,638 for the years ended December 31, 2015 and 2014, respectively. l. Income taxes: The Company and its Subsidiary account for income taxes and uncertain tax positions in accordance with ASC 740, "Income Taxes" ("ASC 740"). ASC 740 prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company and its subsidiary provide a full valuation allowance, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized. The Company implements a two-step approach to recognize and to measure uncertain tax positions in accordance with ASC 740. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2015 and 2014, no liability for unrecognized tax benefits was recorded as a result of the implementation of ASC 740. m. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and the Company’s investment in Parent Company securities. Cash and cash equivalents are deposited with a major bank in Israel. Such cash and cash equivalents and short-term bank deposits may be in excess of insured limits and are not insured in other jurisdictions. The Company's management believes that the financial institution that holds the Company's investments is an institution with high credit standing, and accordingly, minimal credit risk exists with respect to these investments. n. Fair value of financial instruments: The Company adopted ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"). ASC 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to release a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - Observable input that reflects quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Include other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and credit ratings. Level 3 - Unobservable inputs which are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying amounts of cash and cash equivalents, investment in Parent Company, prepaid expenses and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. Derivative related to Service Agreement (see Note 4) is classified within Level 3 because it is valued using valuation techniques. Some of the inputs to these models are unobservable in the market and are significant. o. Impact of recently issued Accounting Standards: In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company is evaluating the effect, if any, that the adoption of this guidance will have on the its financial statements. In November 2015, the FASB issued ASU No. 2015-17, "Income Taxes – Balance Sheet Classification of Deferred Taxes” ("ASU 2015-17"). The purpose of the standard is to simplify the presentation of deferred taxes on a classified balance sheet. Under current GAAP, deferred income tax assets and liabilities are separated into current and noncurrent amounts in the balance sheet. The amendments in ASU 2015-17 require that all deferred tax assets and liabilities be classified as noncurrent in the balance sheet. ASU 2015-17 is effective for interim and annual periods beginning after December 15, 2017, and interim periods within annual periods beginning after December 15, 2018. Companies can adopt the guidance either prospectively or retrospectively. The Company does not expect the adoption of ASU 2015-17 to have a material impact on its consolidated financial statements or presentation.

Investment in Parent Company

Investment in Parent Company	12 Months Ended
	Dec. 31, 2015
Investment in Parent Company [Abstract]
INVESTMENT IN PARENT COMPANY	NOTE 3: - INVESTMENT IN PARENT COMPANY As previously discussed in Notes 1b1 and 2f, the Company currently owns 446,827 of Can-Fite’s ordinary shares, representing approximately 1.59% of Can-Fite's issued and outstanding share capital as of December 31, 2015. As of December 31, 2015 and 2014 the fair value of the Company's investment in Parent Company shares amounted to $658 and $794, respectively (according to its quoted market price in the Tel-Aviv Stock Exchange). During the twelve month period ended December 31, 2015 and 2014, the related unrealized losses derive from the change in the fair value of the securities totaled $136 and $381, respectively.

Derivative Related to Service A

Derivative Related to Service Agreement	12 Months Ended
	Dec. 31, 2015
Derivative Related to Service Agreement [Abstract]
DERIVATIVE RELATED TO SERVICE AGREEMENT	NOTE 4:- DERIVATIVE RELATED TO SERVICE AGREEMENT On November 21, 2011 (the "Closing Date"), upon the consummation of the Reverse Recapitalization, and as part of the Service Agreement with Can-Fite (see Note 1b2), the Company is required to pay Can-Fite an Additional Payment of 2.5% from all future proceeds received by OphthaliX or any of its affiliates in relation to CF101. Can-Fite has the right (the "Exchange Right"), at any time from November 21, 2011 until the earlier of (a) the November 21, 2016 and (b) the closing of the acquisition of the Company by another entity, resulting in the exchange of the Company’s outstanding common shares such that its stockholders prior to such transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity, to convert its right to the additional payment into 480,022 shares of Common Stock (subject to adjustment in certain circumstances). The exercise price for all the shares shall be an aggregate of US $2,500, equal to a per share exercise price of $5.148. The Exchange Right may be exercised on either a cash or a cashless basis, provided that if the warrant is exercised on a cashless basis, the warrant must be exercised in whole, not in part. The Company's management applied ASC 815 to evaluate whether the Exchange Right (contingent call option to holders) instrument is a financial instrument that has the characteristics of a derivative. In particular, the Company's management also evaluated ASC 815-10-15-74(a) scope exception. The Company's management concluded that the Exchange Right doesn't have fixed settlement provisions, and therefore, should be classified as a liability at inception. As of December 31, 2015 and 2014 the fair value of the Derivative related to Service Agreement was immaterial.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 5:- FAIR VALUE MEASUREMENTS In accordance with ASC 820, the Company measures its marketable securities and embedded derivatives at fair value. Marketable securities fair value is based on quoted prices for identical assets in active markets. These securities are classified within Level 1 and Level 2 on the fair value hierarchy. Derivatives are classified within Level 3 because they are valued using valuation techniques. Some of the inputs to these models are unobservable in the market and are significant. The following table provides information by value level for financial assets and liabilities that are measured at fair value, as defined by ASC 820, on a recurring basis as of December 31, 2015 and 2014. December 31, 2015 Fair value measurements Description Fair Value Level 1 Level 2 Level 3 Investment in Parent Company $ 658 $ 658 $ - $ - Derivative related to Service Agreement *)- - - *)- Total Financial Assets, net $ 658 $ 658 $ - $ - December 31, 2014 Fair value measurements Description Fair Value Level 1 Level 2 Level 3 Investment in Parent Company $ 794 $ 794 $ - $ - Derivative related to Service Agreement *)- - - *)- Total Financial Assets, net $ 794 $ 794 $ - $ - The following table presents the changes in Level 3 instruments measured on a recurring basis for the year ended December 31, 2015 and 2014. The Company's Level 3 instruments consist of Derivative (see Note 4). Transaction in the value of Derivative related to Service Agreement: Balance at January 1, 2014 $ 7 Change in fair value of derivatives (7 ) Balance at December 31, 2014 *)- Change in fair value of derivatives - Balance at December 31, 2015 $ *)- *) Represents an amount lower than $1

Share Capital

Share Capital	12 Months Ended
	Dec. 31, 2015
Share Capital [Abstract]
SHARE CAPITAL	NOTE 6:- SHARE CAPITAL a. Shares of Common Stock: The shares of Common Stock represent the legal acquirer, meaning OphthaliX's share capital as of the transaction date. Shares of Common Stock confer upon the holders the right to receive notice to participate and vote in the general meetings of the Company and the right to receive dividends, if declared. On July 18, 2013 the Company's stockholders approved a reverse stock split of one share for each four and one-half shares outstanding (1:4.5) (the "Reverse Split"). The Reverse Split became effective as of the close of business on August 6, 2013. All shares of Common Stock, warrants, options, per share data and exercise prices included in these financial statements and notes for all periods presented have been retroactively adjusted to reflect the Reverse Split with respect to the Company's shares of Common Stock. b. Warrants: In contemplation with the Reverse Recapitalization, it was agreed that for each four shares of Common Stock purchased by the investors and Can-Fite, they will be granted by the Company nine warrants to acquire two shares of Common Stock of the Company. The exercise price of the warrants is $7.74 per share of Common Stock. The warrants are exercisable for a period of five years from their date of grant. The warrants do not contain nonstandard anti-dilution provisions. According to ASC 815-40-15 and 25 instructions, the Company's management evaluated whether the warrants are entitled to the scope exception in ASC 815-10-15-74 (as the warrants meet the definition of a derivative under ASC 815-10-15-83). Based on their straight forward terms (i.e., fixed exercise price, no down-round or other provisions that will preclude them from being considered indexed to the Company's own stock), the Company's management concluded that the warrants should be classified as equity at inception. In contemplation of the transaction, the Company issued a total of 532,870 fully vested warrants to acquire 118,415 shares of Common Stock to consultants and brokers involved in the transaction. These warrants are exercisable upon the payment of $5.148 per share of Common Stock. As of December 31, 2015 and 2014 the intrinsic value of the Adviser Warrants is $ 0. On November 12, 2012, the Board of Directors, complying with the undertaking taken as part of the recapitalization of the Company on November 21, 2011, formerly resolved to issue to certain investors and Can-Fite, 1,455,228 and 1,267,315 warrants to acquire 323,384 and 281,625 shares of Common Stock of the Company, respectively (the "Warrants"). The exercise price of such Warrants is $7.74 per share. The Warrants are exercisable for a period of five years from their date of grant and do not contain any non- standard anti-dilution provisions. c. Stock option plan and grant: In 2012, the Board of Directors approved the adoption of the 2012 Stock Incentive Plan (the "2012 Plan"). An Israeli annex was subsequently adopted in 2013 to comply with the requirements set by the Israeli law in general and in particular with the provisions of section 102 of the Israeli tax ordinance. Under the 2012 Plan and Israeli annex, the Company may grant its officers, directors, employees and consultants, Stock options, Restricted Stocks and Restricted Stock Units ("RSUs") of the Company. Each Stock option granted shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will be granted with a term in excess of 10 years. Upon the adoption of the 2012 Stock Option Plan the Company reserved for issuance 1,088,888 shares of Common Stock, $0.001 par value each. As of December 31, 2015 the Company has 971,388 shares of Common Stock available for future grant under the 2012 Plan. In January 2012, the Company granted to one of its board members, options to purchase 52,222 shares of Common Stock of the Company at an exercise price of $9.00 per share. The options shall vest over a period of 36 months so long as he remains a director until fully vested. In May 2013, the Company's Board of Directors approved an option grant, to purchase 13,055 shares of its Common Stock to the Company's Chief Financial Officer. The options have an exercise price of $9.00 per share and expire on May 29, 2023. Half of these options were fully vested at grant date, and the remaining options will vest over a period of three years on a quarterly basis for 12 consecutive quarters from the date of the grant. Also in 2013, the Company granted one of its directors, options to purchase 52,222 shares of Common Stock of the Company at $6.638 per share. The options shall vest over a period of 12 consecutive quarters so long as he remains a director, until fully vested. During the years ended December 31, 2015 and 2014, the Company did not grant any new stock options. The following table summarizes the activity of stock options: Shares Subject to Options Outstanding Description Number of Shares Weighted Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (1) Outstanding at the beginning and at the end of year 117,500 7.96 7.8 $ - Exercisable at the end of the year 107,708 8.05 6.8 $ - Vested and expected to be vested 117,500 7.96 6.9 $ - (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the closing price of the shares of the Company's Common Stock of $ 0.99 as of December 31, 2015. Stock-based compensation expenses recognized during the years ended December 31, 2015 and 2014 totaled to $22 and $25, respectively. As of December 31, 2015, there was $3 of unrecognized stock-based compensation expense all of which is related to stock options. This unrecognized compensation expense is expected to be recognized over a weighted-average period of approximately 0.3 years.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
INCOME TAXES	NOTE 7:- INCOME TAXES a. The Company and its Israeli Subsidiary are separately taxed under the domestic tax laws of the state of incorporation of each entity. b. Net operating losses carryforward: The Company is subject to U.S. income taxes. As of December 31, 2015, the Company has net operating loss carryforwards for federal income tax purposes of approximately $1,962 which expire in the years 2018 to 2035. The Company has no operating loss carryforwards for state income tax purposes. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the "change in ownership" provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. The Company's Subsidiary in Israel has estimated accumulated losses for tax purposes as of December 31, 2015, in the amount of approximately $2,698 which may be carried forward and offset against taxable income in the future for an indefinite period. c. Loss before taxes is comprised as follows: Year ended 2015 2014 Domestic $ 491 $ 367 Foreign (Israel) 986 828 $ 1,477 $ 1,195 d. Deferred taxes: Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and its subsidiary's' deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and its subsidiaries deferred tax assets are as follows: December 31, 2015 2014 Operating loss carryforward $ 1,500 $ 1,268 Research and development expenses 748 205 Investment in Parent company 337 282 Deferred tax assets before valuation allowance 2,585 2,755 Valuation allowance (2,585 ) (1,755 ) Net deferred tax asset $ - $ - The Company has provided valuation allowance in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company and its subsidiary have a history of losses it is more likely than not that the deferred tax regarding the loss carryforward and other temporary differences will not be realized in the foreseeable future. e. Tax rates applicable to the income of the Company: Corporate tax rate in Israel in 2014 and 2015 is 26.5%. On January 4, 2016, the Israeli Parliament's Plenum approved by a second and third reading the Bill for Amending the Income Tax Ordinance (No. 217) (Reduction of Corporate Tax Rate), 2015, which consists of the reduction of the corporate tax rate from 26.5% to 25%. The Company estimates that the effect of the change in tax rates will result in a decrease in deferred tax balances as of December 31, 2015 in immaterial amounts. The deferred tax balances included in the financial statements as of December 31, 2015 are calculated according to the tax rates that were substantially enacted as of the balance sheet date and therefore comply with the above changes, as applicable to the Company. The corporate tax in the U.S. applying to a Company (incorporated in state of Delaware), consists of a progressive corporate tax at a rate of up to 35% plus state tax and local tax at rates depending on the state and the city in which the company manages its business. In the Company's estimation, it is subject to approximately a 40% tax rate.

Finance Expenses, Net

Finance Expenses, Net	12 Months Ended
	Dec. 31, 2015
Finance Expenses, Net [Abstract]
FINANCE EXPENSES, NET	NOTE 8:- FINANCE EXPENSES, NET Year ended December 31, 2015 2014 Bank fees $ 6 $ 4 Interest expenses 86 52 Revaluation of derivative related to service agreement - (7 ) Foreign currency translation adjustments *)- *)- Finance expenses, net $ 92 $ 49 *) Represents an amount lower than $ 1.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9:- RELATED PARTY TRANSACTIONS As of December 31, 2015 and 2014, and for the years then ended, the Company has several related party balances and transaction mainly in connection with the License Agreement with the Parent Company (refer to Notes 1b2 and 6). Details of the transactions with related parties are depicted in the following tables: Transactions with related parties: Year ended December 31, 2015 2014 Research and development expenses (1) $ 812 $ 701 General and administrative expenses (1) $ 29 $ 115 Finance expenses (income), net (1) $ 86 $ 45 *) Represents an amount lower than $ 1. Balances with Related Parties: December 31, 2015 2014 Parent Company (1) $ (3,690 ) $ (2,457 ) Investment in Parent Company (2) $ 658 $ 794 Other account payables and accrued expenses (1) $ (175 ) $ (175 ) Derivative related to Service Agreement (1) $ *) $ *) (1) Related to Service Agreement (See Note 1b2). (2) Related to Investment in Parent Company. See Notes 2f and Note 3. *) Represents an amount lower than $1.

Significant Accounting Polici16

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Use of estimates	a. Use of estimates: The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Financial statements in U.S. dollars	b. Financial statements in U.S. dollars: The accompanying financial statements have been prepared in U.S. dollars, the functional and reporting currency of the Company. Although the majority of the Company and its Subsidiary's operations are conducted in Israel, most of their expenses are in U.S dollar. Therefore, the Company's management believes that the U.S dollar is the functional currency of the primary economic environment in which the Company and its Subsidiary operate. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars in accordance with ASC 830-10, "Foreign Currency Matters". All transactions gains and losses of the re-measurement of monetary balance sheets items are reflected in the consolidated statements of comprehensive loss as financial income or expenses, as appropriate.
Principles of consolidation	c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its Subsidiary. Intercompany transactions and balances have been eliminated upon consolidation.
Cash and cash equivalents:	d. Cash and cash equivalents: Cash equivalents include short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less from time of deposit.
Prepaid expenses	e. Prepaid expenses: Prepaid expenses are mainly composed of clinical trials drug-kits which expense based on a percentage of completion method of the related clinical trials.
Investment in Parent company	f. Investment in Parent Company: The Company’s investment is its Parent Company’s securities are classified as available-for-sale carried at fair value, with unrealized gains and losses reported as a separate component of stockholders' equity under accumulated other comprehensive income in the consolidated balance sheets. Realized gains and losses on sales of available-for-sale securities are included as financials income, net in the consolidated statements of comprehensive loss. The Company recognizes an impairment charge when a decline in the fair value of its investments in securities is below the cost basis of such securities is judged to be other than temporary. Factors considered in making such a determination include the duration and severity of the impairment, the reason for the decline in value, the potential recovery period and the Company's intent to sell, including whether it is more likely than not that the Company will be required to sell the investment before recovery of cost basis. For securities that are deemed other-than-temporarily impaired, an entity should recognize the difference between the cost basis of the impaired equity security and the fair value on the measurement date, as an other-than-temporarily impairment loss as part of financial income, net in the statement of comprehensive loss. The fair value on measurement date should be considered the equity security’s new cost basis. Unrealized gains and losses previously recorded through OCI, including the tax effects, should also be reversed. The new cost basis should not be changed for subsequent increases in fair value. After an impairment loss is recognized for individual equity securities classified as available for sale, future increases or decreases in fair value (presuming no additional other-than-temporarily impairments exist) are included in OCI. As of December 2015 and 2014 no impairment was recognized.
Property and equipment, net	g. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets at the following annual rates: % Computers, and peripheral equipment 33
Impairment of long-lived assets	h. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360, "Property, Plant and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. As of December 31, 2015 and 2014, no impairment losses have been identified.
Research and development expenses	i. Research and development expenses: All research and development costs are charged to the consolidated statements of comprehensive loss, as incurred.
Accounting for stock-based compensation	j. Accounting for stock-based compensation: The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation" ("ASC 718"). ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company's consolidated statements of comprehensive loss. The Company recognizes compensation expenses for the value of its awards granted based on the accelerated recognition method over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company estimates the fair value of stock options granted using the binomial option pricing-model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the early exercise multiply. Expected volatility was calculated based upon historical volatilities of similar entities in the related sector index. The early exercise multiply is representing the value of the underlying stock as a multiple of the exercise price of the option which, if achieved, results in exercise of the option. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
Basic and diluted net loss per share	k. Basic and diluted net loss per share: Basic net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each period. Diluted net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each period, plus dilutive potential Common Stock considered outstanding during the period, in accordance with ASC topic 260, "Earnings Per Share" ("ASC 260"). The total weighted average number of shares related to the outstanding warrants and options excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,320,948 and 1,453,638 for the years ended December 31, 2015 and 2014, respectively.
Income taxes	l. Income taxes: The Company and its Subsidiary account for income taxes and uncertain tax positions in accordance with ASC 740, "Income Taxes" ("ASC 740"). ASC 740 prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company and its subsidiary provide a full valuation allowance, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized. The Company implements a two-step approach to recognize and to measure uncertain tax positions in accordance with ASC 740. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2015 and 2014, no liability for unrecognized tax benefits was recorded as a result of the implementation of ASC 740.
Concentrations of credit risk	m. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and the Company’s investment in Parent Company securities. Cash and cash equivalents are deposited with a major bank in Israel. Such cash and cash equivalents and short-term bank deposits may be in excess of insured limits and are not insured in other jurisdictions. The Company's management believes that the financial institution that holds the Company's investments is an institution with high credit standing, and accordingly, minimal credit risk exists with respect to these investments.
Fair value of financial instruments	n. Fair value of financial instruments: The Company adopted ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"). ASC 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to release a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - Observable input that reflects quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Include other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and credit ratings. Level 3 - Unobservable inputs which are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying amounts of cash and cash equivalents, investment in Parent Company, prepaid expenses and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. Derivative related to Service Agreement (see Note 4) is classified within Level 3 because it is valued using valuation techniques. Some of the inputs to these models are unobservable in the market and are significant.
Impact of recently issued Accounting Standards	o. Impact of recently issued Accounting Standards: In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company is evaluating the effect, if any, that the adoption of this guidance will have on the its financial statements. In November 2015, the FASB issued ASU No. 2015-17, "Income Taxes – Balance Sheet Classification of Deferred Taxes” ("ASU 2015-17"). The purpose of the standard is to simplify the presentation of deferred taxes on a classified balance sheet. Under current GAAP, deferred income tax assets and liabilities are separated into current and noncurrent amounts in the balance sheet. The amendments in ASU 2015-17 require that all deferred tax assets and liabilities be classified as noncurrent in the balance sheet. ASU 2015-17 is effective for interim and annual periods beginning after December 15, 2017, and interim periods within annual periods beginning after December 15, 2018. Companies can adopt the guidance either prospectively or retrospectively. The Company does not expect the adoption of ASU 2015-17 to have a material impact on its consolidated financial statements or presentation.

Significant Accounting Polici17

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Schedule of property and equipment, net	% Computers, and peripheral equipment 33

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Measurements [Abstract]
Summary of financial assets and liabilities measured at fair value on recurring basis	December 31, 2015 Fair value measurements Description Fair Value Level 1 Level 2 Level 3 Investment in Parent Company $ 658 $ 658 $ - $ - Derivative related to Service Agreement *)- - - *)- Total Financial Assets, net $ 658 $ 658 $ - $ - December 31, 2014 Fair value measurements Description Fair Value Level 1 Level 2 Level 3 Investment in Parent Company $ 794 $ 794 $ - $ - Derivative related to Service Agreement *)- - - *)- Total Financial Assets, net $ 794 $ 794 $ - $ -
Summary of changes in level 3 instruments measured on recurring basis	Balance at January 1, 2014 $ 7 Change in fair value of derivatives (7 ) Balance at December 31, 2014 *)- Change in fair value of derivatives - Balance at December 31, 2015 $ *)- *) Represents an amount lower than $1

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2015
Share Capital [Abstract]
Schedule of stock options activity	Shares Subject to Options Outstanding Description Number of Shares Weighted Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (1) Outstanding at the beginning and at the end of year 117,500 7.96 7.8 $ - Exercisable at the end of the year 107,708 8.05 6.8 $ - Vested and expected to be vested 117,500 7.96 6.9 $ - (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the closing price of the shares of the Company's Common Stock of $ 0.99 as of December 31, 2015.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
Schedule of loss before taxes	Year ended 2015 2014 Domestic $ 491 $ 367 Foreign (Israel) 986 828 $ 1,477 $ 1,195
Schedule of deferred tax assets	December 31, 2015 2014 Operating loss carryforward $ 1,500 $ 1,268 Research and development expenses 748 205 Investment in Parent company 337 282 Deferred tax assets before valuation allowance 2,585 2,755 Valuation allowance (2,585 ) (1,755 ) Net deferred tax asset $ - $ -

Finance Expenses , Net (Tables)

Finance Expenses , Net (Tables)	12 Months Ended
	Dec. 31, 2015
Finance Expenses, Net [Abstract]
Schedule of finance expenses, net	Year ended December 31, 2015 2014 Bank fees $ 6 $ 4 Interest expenses 86 52 Revaluation of derivative related to service agreement - (7 ) Foreign currency translation adjustments *)- *)- Finance expenses, net $ 92 $ 49 *) Represents an amount lower than $ 1.

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Schedule of transactions with related parties	Year ended December 31, 2015 2014 Research and development expenses (1) $ 812 $ 701 General and administrative expenses (1) $ 29 $ 115 Finance expenses (income), net (1) $ 86 $ 45
Schedule of balances with related parties	December 31, 2015 2014 Parent Company (1) $ (3,690 ) $ (2,457 ) Investment in Parent Company (2) $ 658 $ 794 Other account payables and accrued expenses (1) $ (175 ) $ (175 ) Derivative related to Service Agreement (1) $ *) $ *) (1) Related to Service Agreement (See Note 1b2). (2) Related to Investment in Parent Company. See Notes 2f and Note 3

General (Details)

General (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 17, 2013	Nov. 21, 2011	Dec. 31, 2015	Dec. 31, 2014
General (Textual)
Common Stock, par value			$ 0.001	$ 0.001
License agreement terms			License agreement between Can-Fite and NIH remains in effect, a nonrefundable minimum annual royalty fee and potential future royalties of 4.0% to 5.5% on net sales.
Deferred payments			$ 3,690,000	$ 2,457,000
Total operating expenses			(1,385,000)	$ (1,146,000)
Private Placement [Member]
General (Textual)
Total consideration received for sale of stock		$ 3,330,000
Common Stock converted to additional payment		646,776
Warrants exercisable period		5 years
Exercise price of the warrants		$ 7.74
Recapitalization transaction description		for each four shares of the Company's common stock purchased in the financing, nine warrants valid for a period of five years from the closing of the financing to acquire two shares of the Company for an exercise price of $7.74.
Maximum [Member]
General (Textual)
Payment for milestone			500,000
Minimum [Member]
General (Textual)
Payment for milestone			25,000
Eye-Fite Ltd [Member]
General (Textual)
Shares issued for acquired outstanding shares		8,000,000
Common Stock, par value		$ 0.001
Accrual clinical trials cost			$ 75,000
Percentage of sublicensing revenues			20.00%
Can-Fite [Member]
General (Textual)
Common stock shares issued		480,022
Shares issued, price per share		$ 5.148
Percentage of voting power		50.00%
Total consideration received for sale of stock	$ 511,000
Ordinary shares held	268,095		446,827
Percentage of issued and outstanding share capital			1.60%
Percentage of expenses			15.00%
Interest rate on deferred payments			3.00%
Can-Fite [Member] | Private Placement [Member]
General (Textual)
Common stock shares issued		466,139
Common stock value issued		$ 2,400,000
Ordinary shares received		714,922
Gross proceeds		$ 500,000
Shares issued		97,112
Ophthalix [Member]
General (Textual)
Accrual clinical trials cost			$ 100,000

Significant Accounting Polici24

Significant Accounting Policies (Details)	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Computers, and peripheral equipment	33.00%

Significant Accounting Polici25

Significant Accounting Policies (Details Textual) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Significant Accounting Policies (Textual)
Anti-dilutive share	1,320,948	1,453,638

Investment in Parent Company (D

Investment in Parent Company (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 17, 2013	Dec. 31, 2015	Dec. 31, 2014
Investment in Parent Company (Textual)
Investment in Parent Company (Note 3)		$ 658	$ 794
Unrealized gain from investment in Parent company		$ 136	$ 381
Can-Fite [Member]
Investment in Parent Company (Textual)
Outstanding ordinary shares	268,095	446,827
Percentage of issued and outstanding share capital		1.60%

Derivative Related to Service27

Derivative Related to Service Agreement (Details) - Service Agreement [Member] $ / shares in Units, $ in Thousands	1 Months Ended
	Nov. 21, 2011USD ($)$ / sharesshares
Derivative Related to Service Agremeent (Textual)
Aggregate price for shares | $	$ 2,500
Exercise price of share | $ / shares	$ 5.148
Common shares sold for considertion | shares	480,022
Can-Fite [Member]
Derivative Related to Service Agremeent (Textual)
Future additional payments percentage	2.50%

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Recurring [Member] - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in Parent Company		$ 658	$ 794
Derivative related to Service Agreement	[1]
Total Financial Assets, net		$ 658	$ 794
Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in Parent Company		$ 658	$ 794
Derivative related to Service Agreement
Total Financial Assets, net		$ 658	$ 794
Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in Parent Company
Derivative related to Service Agreement
Total Financial Assets, net
Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in Parent Company
Derivative related to Service Agreement	[1]
Total Financial Assets, net
[1]	Represents an amount lower than $1

Fair Value Measurements (Deta29

Fair Value Measurements (Details 1) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015		Dec. 31, 2014
Fair Value Measurements [Abstract]
Beginning Balance			[1]	$ 7
Change in fair value of derivatives				$ (7)
Ending Balance	[1]
[1]	Represents an amount lower than $1

Share Capital (Details)

Share Capital (Details)	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Shares, Outstanding | shares	117,500
Weighted Average Exercise Price, Outstanding | $ / shares	$ 7.96
Weighted Average Remaining Contractual Term, Outstanding (in years)	3 months 18 days
Aggregate Intrinsic Value, Outstanding | $
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Shares, Outstanding | shares	117,500
Number of Shares, Exercisable | shares	107,708
Number of Shares, Vested and expected to be vested | shares	117,500
Weighted Average Exercise Price, Outstanding | $ / shares	$ 7.96
Weighted Average Exercise Price, Exercisable | $ / shares	8.05
Weighted Average Exercise Price, Vested and expected to be vested | $ / shares	$ 7.96
Weighted Average Remaining Contractual Term, Outstanding (in years)	7 years 9 months 18 days
Weighted Average Remaining Contractual Term, Exercisable (in years)	6 years 9 months 18 days
Weighted Average Remaining Contractual Term, Vested and expected to be vested (in years)	6 years 10 months 24 days
Aggregate Intrinsic Value, Outstanding | $		[1]
Aggregate Intrinsic Value, Exercisable | $		[1]
Aggregate Intrinsic Value, Vested and expected to be vested | $		[1]
[1]	The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the closing price of the shares of the Company's Common Stock of $ 0.99 as of December 31, 2015.

Share Capital (Details Textual)

Share Capital (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Apr. 22, 2013	Nov. 12, 2012	Jan. 02, 2012	Jul. 18, 2013	May. 31, 2013	Jan. 31, 2012	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share Capital Textual [Abstract]
Reserved for issuance, common stock par value							$ 0.001	$ 0.001
Stock based compensation							$ 22	$ 25
Unrecognized stock based compensation expense							$ 3
Weighted average unrecognized compensation expense							3 months 18 days
Stock option plan [Member]
Share Capital Textual [Abstract]
Stock option plan term description			Each Stock option granted shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will be granted with a term in excess of 10 years.
Reserved for issuance, common stock							1,088,888
Reserved for issuance, common stock par value							$ 0.001
Common stock available for future grant							971,388
CEO [Member] | Stock option plan [Member]
Share Capital Textual [Abstract]
Expiration, Granted	10 years
Board of Directors [Member] | Stock option plan [Member]
Share Capital Textual [Abstract]
Options issued to purchase common stock									52,222
Options exercise price									$ 6.638
Options vest description									The options shall vest over a period of 12 consecutive quarters so long as he remains a director, until fully vested.
Chief Financial Officer [Member] | Stock option plan [Member]
Share Capital Textual [Abstract]
Options issued to purchase common stock					13,055
Options exercise price					$ 9
Granted Options expiring date					May 29, 2023
Common Stock [Member]
Share Capital Textual [Abstract]
Reverse stock split				Stock split of one share for each four and one-half shares outstanding (1:4.5)
Exercise price							$ 0.99
Common Stock [Member] | Stock option plan [Member]
Share Capital Textual [Abstract]
Number of shares, Granted						52,222
Exercise price, Granted						$ 9
Vested period description						The options shall vest over a period of 36 months so long as he remains a director until fully vested.
Warrant [Member]
Share Capital Textual [Abstract]
Warrants issued to purchase common stock							532,870
Common shares sold for considertion							118,415
Exercise price							$ 5.148
Adivisor warrants							$ 0	$ 0
Warrant [Member] | Investors [Member]
Share Capital Textual [Abstract]
Exercise price of the warrants		$ 7.74
Warrants expiration period		5 years
Warrants issued to purchase common stock		1,455,228
Common shares sold for considertion		323,384
Warrant [Member] | Can Fite [Member]
Share Capital Textual [Abstract]
Exercise price of the warrants		$ 7.74
Warrants expiration period		5 years
Warrants issued to purchase common stock		1,267,315
Common shares sold for considertion		281,625

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Domestic	$ 491	$ 367
Foreign (Israel)	986	828
Current Income Tax Expense (Benefit)	$ 1,477	$ 1,195

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Operating loss carryforward	$ 1,500	$ 1,268
Research and development expenses	748	205
Investment in Parent company	337	282
Deferred tax assets before valuation allowance	2,585	2,755
Valuation allowance	$ (2,585)	$ (1,755)
Net deferred tax asset

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes (Textual)
Net operating loss carryforwards for federal income tax	$ 1,962
Tax credit carryforward description	2018 to 2035
Corporate tax rate	40.00%
Progressive corporate tax rate	35.00%
Maximum [Member]
Income Taxes (Textual)
Corporate tax rate	26.50%
Minimum [Member]
Income Taxes (Textual)
Corporate tax rate	25.00%
Israel [Member]
Income Taxes (Textual)
Foreign accumulated losses	$ 2,698
Foreign corporate tax rate	26.50%	26.50%

Finance Expenses , Net (Details

Finance Expenses , Net (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Finance Expenses, Net [Abstract]
Bank fees		$ 6	$ 4
Interest expenses		$ 86	52
Revaluation of derivative related to service agreement			$ (7)
Foreign currency translation adjustments	[1]
Finance expenses (income), net		$ 92	$ 49
[1]	Represents an amount lower than $1

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Transactions with related parties:
General and administrative expenses (1)		$ (573)	$ (425)
Related Parties [Member]
Transactions with related parties:
Research and development expenses (1)	[1]	812	701
General and administrative expenses (1)	[1]	29	115
Finance expenses (income), net (1)	[1]	$ 86	$ 45
[1]	Related to Service Agreement (See Note 1b2)

Related Party Transactions (D37

Related Party Transactions (Details 1) - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Balances with Related Parties:
Parent company (1)		$ 3,690	$ 2,457
Investment in Parent Company (2)		658	794
Other account payables and accrued expenses (1)	[1]	$ (175)	$ (175)
Derivative related to service agreement (1)	[2]
[1]	Related to Service Agreement (See Note 1b2)
[2]	Represents an amount lower than $1